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Abstract Angelica keiskei (Miq.) Koidz. (Umbelliferae)
has traditionally been used to treat dysuria, dyschezia, and
dysgalactia as well as to restore vitality. Recently, the
aerial parts of A. keiskei have been consumed as a health
food. Various flavonoids, coumarins, phenolics, acetylenes,
sesquiterpene, diterpene, and triterpenes were identified as
the constituents of A. keiskei. The crude extracts and pure
constituents were proven to inhibit tumor growth and
ameliorate inflammation, obesity, diabetics, hypertension,
and ulcer. The extract also showed anti-thrombotic, anti-
oxidative, anti-hyperlipidemic, anti-viral, and anti-bacterial
activities. This valuable herb needs to be further studied
and developed not only to treat these human diseases but
also to improve human health. Currently A. keiskei is
commercialized as a health food and additives in health
drinks. This article presents a comprehensive review of A.
keiskei and its potential place in the improvement of human
health.
Keywords Angelica keiskei  Umbelliferae  Chemical
constituent  Biological activity
Introduction
Angelica keiskei (Miq.) Koidz. is a hardy perennial,
belonging to the family Umbelliferae. A. keiskei has tra-
ditionally been used as a diuretic, mild cathartic, tonic, and
galactagogue (Kimura and Baba 2003). The herb is called
‘Myeong-Il Yeob’ in Korea and ‘Ashitaba’ in Japan, both
literally meaning ‘Tomorrow’s Leaf’ (Baba et al. 1998).
Another common name for A. keiskei is ‘Shin-Sun Cho’,
which means ‘a precious herb used by God’. A. keiskei is
mainly distributed in Asian countries including Korea and
Japan (Park 2013). The aerial parts are mainly used as a
source of green vegetable juice as a daily health food and
the young leaves of the aerial parts are used by parboiling
or deep-frying (Imai and Imai 2008). The aerial parts are
also used in tea, flour, wine, and cosmetics (Bao 2014; Su
2014; Ku et al. 2014; Liu et al. 2014). This review paper
summarizes botanical characteristics, phytochemical
research, as well as biological studies on the extracts and
pure constituents of A. keiskei. The extracts have been
reported to have anti-inflammatory, anti-obesity, anti-ox-
idative, anti-coagulant, anti-tumor, anti-mutagenic, anti-
diabetic, anti-bacterial, and hepato-protective activities.
The biological activities of each pure compounds are also
separately summarized in this review.
Botanical characteristics of A. keiskei
Angelica keiskei has glossy leaves and flowers from sum-
mer to fall. The leaves are harvested from spring to fall
before they lose the gloss. A yellow exudate is squeezed
out of the stems when the leaves are harvested (Imai and
Imai 2008). This yellow color makes it easy to distinguish
A. keiskei from A. japonica, an exudate of which shows a
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nearly white color (Kimura et al. 2008). The characteristic
botanical features of A. keiskei are described in Flora of
Japan:
Rhizomes thick and short, with few elongate roots.
Stems stout, branched above, 80–120 cm long, glab-
rous. Leaves radical and lower cauline, usually
evergreen, 2–3-ternate-pinnate, obtusely deltoid in
outline, 20–60 cm. long, glabrous; leaflets rather
thick, usually deeply 2–3 cleft of parted; segments
usually ovate, 5–10 cm long, 3–6 cm wide, acute,
toothed, with impressed veinlets on upper side;
sheaths on the upper part elliptic, inflated. Inflores-
cence umbels rather numerous; peduncles in upper
part; the inner side of rays and pedicels puberulent;
rays 10–20; pedicels 20–40; bracteoles of involucel
several, linear or slightly broaden at base, caudately
elongate, slightly longer or shorter than pedicels;
styles short, as long as stylopodium. Fruit oblong,
glabrous, 6–8 mm long, flat; dorsal ribs short and
rather thick; lateral ribs winged; vittae 1 in intervals,
4 on the commissure (Oi et al. 1965).
Phytochemical investigations on A. keiskei
Previous phytochemical investigations on A. keiskei have
led to the identification of over 100 compounds including
various types of flavonoids (1–31, 41–56), coumarins (57–
92), phenolic (96), acetylenes (98–102), sesquiterpene
(103), diterpene (104), and triterpenes (105–106). Struc-
tures of the reported constituents listed in Tables 1, 2 and 3
are shown in Fig. 1. In our recent study on the aerial parts
of A. keiskei, eight constituents, 4,20,40-trihydroxy-30-
[(2E,5E)-7-methoxy-3,7-dimethyl-2,5-octadienyl]chalcone
(32), (±)-4,20,40-trihydroxy-30-[(2E)-6-hydroxy-7-meth-
oxy-3,7-dimethyl-2-octenyl]chalcone (33), 4,20,40-trihy-
droxy-30-[(2E)-3-methyl-5-(1,3-dioxolan-2-yl)-2-pentenyl]
chalcone (34), 20,30-furano-4-hydroxy-40-methoxychalcone
(35), (±)-4-hydroxy-20,30-(2,3-dihydro-2-methoxyfurano)-
40-methoxychalcone (36), 30-carboxymethyl-4,20-dihy-
droxy-40-methoxychalcone (37), (±)-4,20,40-trihydroxy-30-
[(3-hydroxy-2,2-dimethyl-6-methylenecyclohexyl)methyl]
chalcone (38), and 200-hydroxyangelichalcone (39) were
isolated and reported as new compounds from an ethyl
acetate extract along with eight known compounds, xan-
thoangelol (1), xanthoangelol F (2), 4-hydroxyderricin (3),
xanthoangelol G (6), xanthoangelol D (9), xanthoangelol E
(10), xanthoangelol H (12), (±)-4,20,40-trihydroxy-30-[(6E)-
2-hydroxy-7-methyl-3-methylene-6-octenyl]chalcone (27),
artocarmitin A (40), (?)-cis-(30R,40R)-methylkhellactone
(93), (-)-trans-(30R,40S)-methylkhellactone (94), 3,4-dihy-
droxanthotoxin (95), and (Z)-p-coumaryl alcohol (97) (Kil
et al. 2015a, 2016). In particular, xanthoangelol (1) and
4-hydroderricin (3) were isolated in bulk (1: 5 g, 2: 1.8 g),
which supported that the two chalcones are the predomi-
nant constituents in this herb. As a part of our research on
the aerial parts of A. keiskei, an effective method was
developed to prepare two chalcones from the crude extract
using high-speed counter-current chromatography (two-
phase solvent system: n-hexane–ethyl acetate–methanol–
water 9:5:9:4, revolution rate: 800 rpm, flow rate: 1.5 mL/
min) (Kil et al. 2015b).
Biological activities of extracts
Anti-inflammatory activity
An n-hexane fraction from an ethanol extract of the aerial
parts of A. keiskei showed inhibitory effects on production
of lipopolysaccharide (LPS)-induced nitric oxide (NO) and
prostaglandin E2 (PGE2) by downregulating inducible NO
synthase (iNOS) and cyclooxygenase-2 (COX-2) protein
and mRNA (Lee et al. 2010). An ethyl acetate fraction also
inhibited production of NO in LPS-activated RAW 264.7
cells (Chang et al. 2014).
Anti-obesity activity
In a study in mice, an ethyl acetate extract was reported to
prevent high-fat diet induced adiposity by modulating lipid
metabolism through increasing phosphorylation of adeno-
sine monophosphate-activated protein kinase (AMPK) in
adipose tissue and liver (Zhang et al. 2015). A patent has
been filed on the anti-obesity activity of the ethanol extract
of the aerial parts of A. keiskei in mice (Lee et al. 2012a).
Anti-hyperlipidemic activity
Dietary A. keiskei as an ethyl acetate extract from yellow
exudates produced elevation of serum high-density
lipoprotein (HDL) levels containing apolipoprotein A1
(ApoA1) and ApoE and reduction of liver triglyceride (TG)
levels with decreased mRNA expression of hepatic Acyl-
coenzyme A (CoA) synthetase in stroke-prone sponta-
neously hypertensive rats (SHRSP) (Ogawa et al. 2003).
An ethyl acetate fraction from a methanol extract showed
inhibitory effects against 3-hydroxy-3-methylglutaryl CoA
(HMG-CoA) reductase, a crucial and rate limiting enzyme
in biosynthesis of cholesterol (Park et al. 1997b). The
impact of A. keiskei was examined in rats fed a high fat
diet, and it was shown that liver weight was decreased and
gene expression of the anti-oxidant enzymes, catalase and
glutathione-s-reductase, in the liver was increased (Kim
et al. 2012). In addition, treatment of the ethanol extract
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reduced increased levels of serum insulin and triglycerides
in rats after drinking fructose. The ethanol extract
enhanced expression of genes related to fatty acid b-oxi-
dation and HDL production, acyl-CoA oxidase 1 (ACO1),
medium-chain acyl-CoA dehydrogenase (MCAD), ATP-
binding membrane cassette transporter A1 (ABCA1), and
ApoA1 genes in the fructose fed rats (Ohnogi et al. 2012a).
Anti-oxidative activity
The alcohol extracts of A. keiskei were evaluated for their
scavenging capability against superoxide anion and 1,1-
diphenyl-2-picrylhydrazyl (DPPH) free radicals, and
resulted in decreases of free radical formations. The
scavenging effects of the leaves extract were greater than
those of the stems extract (Qin et al. 2014; Guo et al.
2013).
Anti-thrombotic activity
Exudates of A. keiskei resulted in anti-coagulation by
inhibiting elevated plasma plasminogen activator inhibitor
1 (PAI-1) under inflammatory conditions induced by LPS
(Ohkura et al. 2011). A methanol extract of its roots
showed anti-platelet activity when evaluated in a washed
rabbit platelets model system (Son et al. 2014).
Table 1 The reported biological activities of xanthoangelol (1)
Parta Biological activity Reference(s)
RT First isolation from the part Kozawa et al. (1977)
RT Anti-ulcer activity: gastric H?–K? ATPase Murakami et al. (1990)
RT Anti-bacterial activity: gram-positive bacteria Inamori et al. (1991)
Syn Anti-bacterial activity: gram-positive bacteria Sugamoto et al. (2011)
RT Anti-tumor-promoter activity: TPA-stimulated 32Pi-incorporation, Ca?-calmodulin system Okuyama et al. (1991)
EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2003)
RT Anti-tumor and anti-metastatic activities: DNA synthesis, tumor-induced neovascularization, binding of
VEGF to HUVECs
Kimura and Baba
(2003)
EXD Anti-tumor activity: apoptosis (caspase-3) in human neuroblastoma (IMR-32), leukemia (Jurkat) cells Tabata et al. (2005)
EXD Anti-tumor activity: apoptosis (caspase-9, cytochrome c), ROS, DJ-1 protein in human neuroblastoma (IMR-
32) cells
Motani et al. 2008)
EXD,
ST
Cytotoxicities: human neuroblastoma cells (LA-N-1, NB-39: drug-resistant; IMR-32, SK-N-SH: drug-
sensitive)
Motani et al. (2008),
Nishimura et al.
(2007)
ST Anti-tumor activity: apoptosis (DNA fragmentation) in human stomach cancer (KATO III) cells Takaoka et al. (2008)
AP Anti-diabetic activity: insulin-like activity Enoki et al. (2007)
RT Anti-diabetic activity: GLUT4 translocation Kawabata et al. (2011)
AP Anti-diabetic activity: a-glucosidase Luo et al. (2012)
ST Anti-diabetic activity: PTP1B Li et al. (2015)
RT Anti-hypertensive activity: vasoconstriction in rat aortic rings Matsuura et al. (2001)
RT Preventive effect against metabolic syndrome: adiponectin production Ohnogi et al. (2012b)
RT Preventive effect against metabolic syndrome: adipocytes differentiation (AMPK, MAPK pathways;
C/EBPs, PPARc)
Zhang et al. (2013)
EXD Anti-inflammatory activity (details in the patent) Akihisa et al. (2007)
RT Anti-inflammatory activity: NO, TNF-a, iNOS, COX-2, AP-1 Yasuda et al. (2014)
LF Anti-inflammatory activity: IL-6 in TNF-a-stimulated osteosarcoma cells Shin et al. (2011)
AP Anti-oxidative activity: NQO1 induction, DPPH radical scavenging Luo et al. (2012)
ST Anti-oxidative activity: XO Kim et al. (2014)
ST Anti-thrombotic activity: PAI-1 Ohkura et al. (2011)
RT Anti-thrombotic activity: platelet aggregation (induced by collagen, platelet-activating factor, phorbol
12-myristate 13-acetate, not thrombin)
Son et al. (2014)
ST Whitening activity: melanin formation in B16 melanoma cells Arung et al. (2012)
AP Anti-depressant activity: MAO (nonselective), DBH Kim et al. (2013)
WP Anti-viral activity: SARS-CoV (viral proteases: 3CLpro, PLpro) Park et al. (2015)
a Plant part code: WP whole plant, RT root, AP aerial part (including stem and leaf), ST stem, LF leaf, EXD exudate; other source code: Syn
synthetic
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Anti-tumor and anti-mutagenic activity
The extracts induced apoptotic cell death in various
human cancer cell lines including breast cancer (MDA-
MB-231) (Jeong and Kang 2011), leukemia (HL60),
melanoma (CRL1579), lung cancer (A549), stomach
cancer (AZ521) (Akihisa et al. 2011), prostate cancer
(LNCaP) (Lee et al. 2014). In these cancer cell lines
studies, increasing expression level of the proapoptotic
gene, Caspase-3, and apoptotic inducer gene, B cell
lymphoma 2 (Bcl-2), and decreasing expression level of
the apoptotic suppressor gene, Bcl-2 associated x (Bax),
were presented as the mechanism of action of anti-cancer
effects of A. keiskei (Jeong and Kang 2011). The methanol
extract showed an anti-mutagenic activity against afla-
toxin B1 (AFB1), N-methyl-N0-nitro-N-nitrosoguanidine,
Table 2 The reported biological activities of 4-hydroxyderricin (3)
Parta Biological activity Reference(s)
RT First isolation from the part Kozawa et al. (1977)
RT Anti-ulcer activity: gastric H?–K? ATPase Murakami et al. (1990)
RT Anti-bacterial activity: gram-positive bacteria Inamori et al. (1991)
Syn Anti-bacterial activity: gram-positive bacteria Sugamoto et al. (2011)
Syn Anti-bacterial activity: S. aureus seryl-tRNA synthetase Battenberg et al. (2013)
RT Anti-tumor-promoter activity: TPA-stimulated 32Pi-incorporation, Ca?-calmodulin system Okuyama et al. (1991)
EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2003)
ST Anti-tumor activity: apoptosis (DNA fragmentation) in human stomach cancer (KATO III) cells Takaoka et al. (2008)
RT Anti-tumor and anti-metastatic activities: DNA synthesis, tumor-induced neovascularization, lymphocytes,
CD4?, CD8?, NK-T cells
Kimura et al. (2004)
RT Anti-tumor activity: apoptosis (DNA topoisomerase, procasparases-3, -8, -9 in human leukemia (HL60) cells
Cytotoxicities: human leukemia (HL60), melanoma (CRL1579), lung cancer (A549), stomach cancer
(AZ521) cells
Akihisa et al. (2011)
ST Cytotoxicities: human neuroblastoma cells (IMR-32, NB-39) Nishimura et al. (2007)
RT Anti-hypertensive activity: vasoconstriction in rat aortic rings Matsuura et al. (2001)
ST Anti-hypertensive activity: systolic blood pressure in SHRSP
Anti-hyperlipidemic activity: serum VLDL (microsomal TG transfer-protein), hepatic TG (differentiation
factor 1, fatty acid synthase) levels in SHRSP
Ogawa et al. (2005b)
AP Anti-diabetic activity: insulin-like activity Enoki et al. (2007)
RT Anti-diabetic activity: chronic ingestion on borderline mild hyperglycemia (adiponectin) Ohnogi et al. (2007)
RT Anti-diabetic activity: GLUT4 translocation Kawabata et al. (2011)
AP Anti-diabetic activity: a-glucosidase Luo et al. (2012)
ST Anti-diabetic activity: PTP1B Li et al. (2015)
EXD Anti-inflammatory activity (details in the patent) Akihisa et al. (2007)
LF Anti-inflammatory activity: IL-6 in TNF-a-stimulated osteosarcoma cells Shin et al. (2011)
RT,
AP
Anti-inflammatory activity: NO, TNF-a, iNOS, COX-2, AP-1 Yasuda et al. (2014),
Chang et al. (2014)
AP Anti-inflammatory activity: I-jB degradation, NF-jB nuclear translocation Chang et al. (2014)
RT Anti-thrombotic activity: platelet aggregation (induced by collagen, platelet-activating factor, phorbol
12-myristate 13-acetate, not thrombin)
Son et al. (2014)
LF Anti-viral activity: influenza virus neuraminidase Park et al. (2011)
WP Anti-viral activity: SARS-CoV (viral proteases: 3CLpro, PLpro) Park et al. (2015)
RT Preventive effect against metabolic syndrome: adiponectin production Ohnogi et al. (2012b)
RT Preventive effect against metabolic syndrome: adipocytes differentiation (AMPK, MAPK pathways;
C/EBPs, PPARc)
Zhang et al. (2013)
AP Anti-oxidative activity: NQO1 induction Luo et al. (2012)
WP Anti-oxidative activity: XO Kim et al. (2014)
ST Whitening activity: melanin formation in B16 melanoma cells Arung et al. (2012)
AP Anti-depressant activity: inhibition of MAO-B (selective), DBH Kim et al. (2013)
a Plant part code: WP whole plant, RT root, AP aerial part (including stem and leaf), ST stem, LF leaf, EXD exudate; other source code: Syn
synthetic
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Table 3 Constituents from A. keiskei and their reported biological activities
Compound class/name Parta Biological activity Reference(s)
Flavonoids
Chalcones
Xanthoangelol F (2) RT First isolation from the part Nakata et al. (1999)
RT Anti-hypertensive activity: phenylephrine-induced
vasoconstriction in rat aortic rings
Matsuura et al.
(2001)
EXD Anti-tumor-promoter activity: EBV-EA by TPA
Anti-tumor-initiator activity: NOR 1
Akihisa et al. (2003)
EXD Anti-inflammatory activity (details in the patent) Akihisa et al. (2007)
ST Cytotoxicities: human neuroblastoma (IMR-32, NB-39) Nishimura et al.
(2007)
Syn Anti-bacterial activity: Gram-positive bacteria Sugamoto et al.
(2011)
AP Anti-viral activity: influenza virus neuraminidase Park et al. (2011)
WP Anti-viral activity: SARS-CoV (3CLpro, PLpro) Park et al. (2015)
WP Anti-oxidative activity: XO Kim et al. (2014)
ST Anti-diabetic activity: PTP1B Li et al. (2015)
Isobavachalcone (4) RT First isolation from the part Nakata et al. (1999)
EXD Anti-tumor-promoter activity: EBV-EA by TPA, in vivo Akihisa et al. (2003)
Two-stage mouse skin carcinogenesis test
Anti-tumor-initiator activity: NOR 1
Akihisa et al. (2006)
ST Anti-tumor activity: apoptosis (procaspase-3, -9, Bax) in human
neuroblastoma cells (IMR-32, NB-39)
Nishimura et al.
(2007)
EXD Anti-inflammatory activity (details in the patent) Akihisa et al. (2007)
Com Anti-inflammatory activity: iNOS Shin et al. (2013)
Syn Anti-bacterial activity: Gram-positive bacteria Sugamoto et al.
(2011)
AP Anti-oxidative activity: NQO1 induction, DPPH radical
scavenging
Luo et al. (2012)
WP Anti-oxidative activity: XO Kim et al. (2014)
AP Anti-diabetic activity: a-glucosidase Luo et al. (2012)
WP Anti-viral activity: SARS-CoV (3CLpro, PLpro) Park et al. (2015)
Xanthoangelol B (5) RT First isolation from the part Baba et al. (1990b)
RT Anti-hypertensive activity: phenylephrine-induced
vasoconstriction in rat aortic rings
Matsuura et al.
(2001)
RT Anti-allergic activity: compound 48/80-induced histamine
release
Nakata and Baba
(2001)
ST Anti-oxidative activity: superoxide-scavenging Aoki et al. (2008)
WP Anti-oxidative activity: XO Kim et al. (2014)
LF Anti-inflammatory activity: IL-6 in TNF-a-stimulated
osteosarcoma cells
Shin et al. (2011)
AP Anti-inflammatory activity: NO, iNOS, COX-2 (IjB
degradation, NF-jB nuclear translocation)
Chang et al. (2014)
AP Anti-viral activity: influenza virus neuraminidase Park et al. (2011)
ST Anti-thrombotic activity: TNFa-induced PAI-1 Ohkura et al. (2011)
WP Anti-viral activity: SARS-CoV (3CLpro, PLpro) Park et al. (2015)
Xanthoangelol G (6) RT First isolation from the part Nakata et al. (1999)
AP Anti-viral activity: influenza virus neuraminidase Park et al. (2011)
WP Anti-viral activity: SARS-CoV (3CLpro, PLpro) Park et al. (2015)
4,20-Dihydroxy-30-[(2E)-6-hydroperoxy-3-
methyl-7-methylene-2-octenyl]-40-methoxy
chalcone (7)
RT Preventive effect against metabolic syndrome: adiponectin
production
Ohnogi et al.
(2012b)
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Table 3 continued
Compound class/name Parta Biological activity Reference(s)
Xanthoangelol C (8) RT Baba et al. (1990b)
RT Anti-allergic activity: compound 48/80-induced histamine Nakata and Baba
(2001)
Xanthoangelol D (9) RT First isolation from the part Baba et al. (1990b)
RT Anti-inflammatory activity: TNF-a induced ET-1 (NF-jB) Sugii et al. (2005)
AP Anti-viral activity: influenza virus neuraminidase Park et al. (2011)
ST Anti-thrombotic activity: TNFa-induced PAI-1 Ohkura et al. (2011)
WP Anti-viral activity: SARS-CoV (3CLpro, PLpro) Park et al. (2015)
ST Anti-diabetic activity: PTP1B Li et al. (2015)
Xanthoangelol E (10) RT First isolation from the part Baba et al. (1990b)
RT Anti-ulcer activity (details in the patent) Murakami et al.
(1992)
RT Anti-thrombotic activity: arachidonic acid metabolism in
platelets
Fujita et al. (1992)
RT Anti-hypertensive activity: phenylephrine-induced
vasoconstriction in rat aortic rings
Matsuura et al.
(2001)
RT Anti-allergic activity: compound 48/80-induced histamine Nakata and Baba
(2001)
LF First isolation from the part Shin et al. (2011)
AP Anti-inflammatory activity: NO, iNOS, COX-2 (IjB
degradation, NF-jB nuclear translocation)
Chang et al. (2014)
WP Anti-viral activity: SARS-CoV (3CLpro, PLpro) Park et al. (2015)
ST Anti-diabetic activity: PTP1B Li et al. (2015)
Ashitaba-chalcone (11) RT Anti-tumor-promoter activity: TPA-stimulated 32Pi-
incorporation
Okuyama et al.
(1991)
Xanthoangelol H (12) RT First isolation from the part Nakata et al. (1999)
EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2003)
ST Cytotoxicities: human neuroblastoma (IMR-32, NB-39) Nishimura et al.
(2007)
ST Whitening activity: melanin formation in melanoma cells Arung et al. (2012)
Deoxyxanthoangelol H (13) EXD First isolation from the part Akihisa et al. (2006)
EXD Anti-inflammatory activity (details in the patent) Akihisa et al. (2007)
ST Whitening activity: melanin formation in melanoma cells Arung et al. (2012)
Xanthoangelol I (14) EXD Anti-tumor-promoter activity: EBV-EA by TPA
Anti-tumor-initiator activity: NOR 1
Akihisa et al. (2006)
ST Cytotoxicities: human neuroblastoma (IMR-32, NB-39) Nishimura et al.
(2007)
200-Hydroxy-xanthoangelol I (15) RT Protective effect on nerve cells (details in the patent) Onogi et al. (2004)
RT Preventive effect against metabolic syndrome: adiponectin Ohnogi et al.
(2012b)
Xanthoangelol J (16) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2006)
Anti-tumor-initiator activity: NOR 1
Xanthoangelol K (17) ST Anti-diabetic activity: PTP1B Li et al. (2015)
Xanthoangelol L (18) ST First isolation from the part Li et al. (2015)
Jejuchalcone D (19) ST First isolation from the part Li et al. (2015)
Xanthoangelol M (20) ST Anti-diabetic activity: PTP1B Li et al. (2015)
4-Hydroxy-20,30-(2,3-dihydro-2-hydroxy
isopropylfurano)-40-methoxychalcone (21)
RT Preventive effect against metabolic syndrome: adiponectin
production
Ohnogi et al.
(2012b)
Jejuchalcone E (22) ST First isolation from the part Li et al. (2015)
Dorsmannin A (23) EXD First isolation from the part Akihisa et al. (2006)
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Table 3 continued
Compound class/name Parta Biological activity Reference(s)
Xanthokeismin A (24) ST Anti-oxidative activity: superoxide-scavenging Aoki et al. (2008)
AP Anti-inflammatory activity: NO, iNOS, COX-2 (IjB
degradation, NF-jB nuclear translocation)
Chang et al. (2014)
Xanthokeismin B (25) ST Anti-oxidative activity: superoxide-scavenging Aoki et al. (2008)
Xanthokeismin C (26) ST Anti-oxidative activity: superoxide-scavenging Aoki et al. (2008)
4,20,40-Trihydroxy-30-[(6E)-2-hydroxy-7-
methyl-3-methylene-6-octenyl]chalcone
(27)
LF
AP
Anti-inflammatory activity: IL-6 in TNF-a-stimulated
osteosarcoma cells
Protective activity on damaged normal cells: HSPs
Shin et al. (2011)
Kil et al. (2015a)
Xanthokeistal A (28) AP
WP
Anti-viral activity: influenza virus neuraminidase
Anti-viral activity: SARS-CoV (3CLpro, PLpro)
Park et al. (2011)
Park et al. (2015)
4,2040-Trihydroxy-30-[(2E)-6,7-dihydroxy-
3,7-dimethyl-2-octenyl] chalcone (29)
RT
AP
First isolation from the part
First isolation from the part
Ohnogi et al.
(2012b)
Luo et al. (2012)
4,20-Dihydroxy-30,40-{2,3-dihydro-2-[(4E)-1-
hydroxy-1,5-dimethyl-4-hexenyl]furano}
chalcone (30)
RT Preventive effect against metabolic syndrome: adiponectin
production
Ohnogi et al.
(2012b)
Angelichalcone (31) RT
RT
Protective effect on nerve cells (details in the patent)
Osteogenesis promotive activity (details in the patent)
Onogi et al. (2004)
Ohnogi et al. (2004)
4,20,40-Trihydroxy-30-[(2E,5E)-7-methoxy-
3,7-dimethyl-2,5-octadienyl] chalcone (32)
AP First isolation from the part Kil et al. (2015a)
(±)-4,20,40-Trihydroxy-30-[(2E)-6-hydroxy-
7-methoxy-3,7-dimethyl-2-
octenyl]chalcone (33)
AP First isolation from the part Kil et al. (2015a)
4,20,40-Trihydroxy-30-[(2E)-3-methyl-5-(1,3-
dioxolan-2-yl)-2-pentenyl]chalcone (34)
AP First isolation from the part Kil et al. (2015a)
20,30-Furano-4-hydroxy-40-methoxychalcone
(35)
AP First isolation from the part Kil et al. (2015a)
(±)-4-Hydroxy-20,30-(2,3-dihydro-2-
methoxyfurano)-40-methoxychalcone (36)
AP First isolation from the part Kil et al. (2015a)
30-Carboxymethyl- 4,20-dihydroxy-40-
methoxy chalcone (37)
AP First isolation from the part Kil et al. (2016)
(±)-4,20,40-Trihydroxy-30-[(3-hydroxy-2,2-
dimethyl-6-
methylenecyclohexyl)methyl]chalcone (38)
AP First isolation from the part Kil et al. (2016)
200-Hydroxy angelichalcone (39) AP First isolation from the part Kil et al. (2016)
Artocarmitin A (40) AP First isolation from the part Kil et al. (2016)
Dihydrochalcones
Deoxydihydroxanthoan EXD First isolation from the part Akihisa et al. (2006)
Gelol H (41) ST whitening activity: melanin formation in melanoma cells Arung et al. (2012)
Erioschalcone A (42) AP First isolation from the part Luo et al. (2012)
Flavones
Cynaroside (43) (=luteolin-7-O-b-D-
glucopyranoside)
AP Anti-hyperlipidemic acitivity Park et al. (1995)
AP Anti-cholesterogenic activity: HMG-CoA reductase Park et al. (1997b)
AP Anti-mutagenic activity (AFB1) Park et al. (1997a)
AP Anti-oxidative activity: epoxide hydrolase in liver Park et al. (2002)
AP Anti-oxidative activity: DPPH radical scavenging Kim et al. (2005)
AP Anti-depressant activity: DBH Kim et al. (2013)
ST Anti-diabetic activity: PTP1B Li et al. (2015)
Luteolin-7-O-b-D-rutinoside (44) AP First isolation from the part Park et al. (1995)
AP Anti-mutagenic activity (AFB1) Park et al. (1997a)
AP Anti-oxidative activity: DPPH radical scavenging Kim et al. (2005)
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Table 3 continued
Compound class/name Parta Biological activity Reference(s)
Luteolin (45) LF First isolation from the part Sugamoto et al.
(2008)
Flavonol glycosides
Kaempferol-3-O-a-D-arabinopyranoside (46) AP Anti-oxidative activity: DPPH radical scavenging Kim et al. (2005)
Isoquercitrin (=quercetin-3-O-b-D-
glucopyranoside) (47)
AP Anti-oxidative activity: DPPH radical scavenging Kim et al. (2005)
Hyperoside (=quercetin-3-O-b-D-
galactopyranoside) (48)
AP First isolation from the part Park et al. (1996)
AP Anti-cholesterogenic activity: HMG-CoA reductase Park et al. (1997b)
AP Anti-mutagenic activity (AFB1) Park et al. (1997a)
AP Anti-oxidative activity: DPPH radical scavenging Kim et al. (2005)
Quercitrin (49) (=quercetin-3-O-b-D-
rhamnopyranoside)
LF First isolation from the part Sugamoto et al.
(2008)
Quercetin-3-O-a-D-arabinopyranoside (50) AP Anti-oxidative activity: DPPH radical scavenging Kim et al. (2005)
Flavanones
Munduleaflavanone A (51) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2003)
AP Anti-diabetic activity: a-glucosidase Luo et al. (2012)
Munduleaflavanone B (52) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2006)
Anti-tumor-initiator activity: NOR 1
EXD anti-inflammatory activity: TPA-induced mouse ear edema Akihisa et al. (2007)
Isobavachin (53) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2006)
Prostratol F (54) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2003)
Sophoraflavanone A (55) (=8-
geranylnaringenin)
EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2006)
Anti-tumor-initiator activity: NOR 1
EXD Anti-inflammatory activity: TPA-induced mouse ear edema Akihisa et al. (2007)
40-O-Geranylnaringenin (56) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2003)
Coumarins
Umbelliferone (57) RT First isolation from the part Baba et al. (1990b)
Scopoletin (58) RT First isolation from the part Baba et al. (1990b)
Demethylsuberosin (59) AP Anti-diabetic activity: a-glucosidase Luo et al. (2012)
Osthenol (60) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2006)
Anti-tumor-initiator activity: NOR 1
EXD Anti-inflammatory activity (details in the patent) Akihisa et al. (2007)
7-O-b-D-Glucopyranosyloxy-8-prenyl
coumarin (61)
RT NGF production enhancive effect on in mouse fibroblasts
(details in the patent)
Ohnogi et al. (2002)
Psoralen (62) RT First isolation from the part Hata and Kozawa
(1961)
AP First isolation from the part Luo et al. (2012)
Ergapten (63) RT First isolation from the part Hata and Kozawa
(1961)
FR First isolation from the part Baba et al. (1990a)
AP First isolation from the part Luo et al. (2012)
ST Anti-diabetic activity: PTP1B Li et al. (2015)
Xanthotoxin (64) RT First isolation from the part Hata and Kozawa
(1961)
FR First isolation from the part Baba et al. (1990a)
EXD First isolation from the part Akihisa et al. (2006)
AP First isolation from the part Luo et al. (2012)
Isopimpinellin (65) RT First isolation from the part Baba et al. (1990b)
FR First isolation from the part Nakata et al. (1997)
EXD First isolation from the part Akihisa et al. (2006)
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Table 3 continued
Compound class/name Parta Biological activity Reference(s)
Imperatorin (66) FR First isolation from the part Baba et al. (1990a)
RT First isolation from the part Nakata et al. (1997)
AP First isolation from the part Luo et al. (2012)
Isogosferol (67) FR First isolation from the part Baba et al. (1990a)
Isoimperatorin (68) FR First isolation from the part Baba et al. (1990a)
RT First isolation from the part Nakata et al. (1997)
Saxaline (69) FR First isolation from the part Nakata et al. (1997)
Marmesin (70) RT First isolation from the part Baba et al. (1990b)
(-)-Oxypeucedanin (71) FR First isolation from the part Baba et al. (1990a)
RT First isolation from the part Nakata et al. (1997)
(?)-Oxypeucedanin hydrate (72) FR, First isolation from the part Nakata et al. (1997)
RT First isolation from the part
(-)-Oxypeucedanin hydrate (73) FR First isolation from the part Baba et al. (1990a)
(-)-Tert-O-methoxy peucedanin hydrate (74) FR First isolation from the part Baba et al. (1990a)
(-)-Sec-O-acetoxy peucedanin hydrate(75) FR First isolation from the part Baba et al. (1990a)
Pseudoisopsoralen (76) AP First isolation from the part Luo et al. (2012)
Angelicin (77) RT First isolation from the part Hata and Kozawa
(1961)
Columbianadin (78) RT First isolation from the part Kozawa et al. (1978)
FR First isolation from the part Baba et al. 1990a)
(30R)-Hydroxy columbianadin (79) (=(8S,9R)-
8-angeloyl oxy-8,9-dihydrooroselol)
EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2003)
RT First isolation from the part Sugamoto et al.
(2009)
(8S,9R)-9-Angeloyloxy-8,9-dihydrooroselol
(80)
RT First isolation from the part Kozawa et al. (1978)
RT Anti-tumor-promoter activity: TPA-stimulated 32Pi-
incorporation
Okuyama et al.
(1991)
Archangelicin (81) RT First isolation from the part Kozawa et al. (1978)
FR First isolation from the part Baba et al. (1990a)
RT Anti-tumor-promoter activity: TPA-stimulated 32Pi-
incorporation
Okuyama et al.
(1991)
Lomatin (82) FR First isolation from the part Baba et al. (1990a)
Selinidin (83) RT First isolation from the part Baba et al. (1990b)
FR First isolation from the part Baba et al. (1990a)
EXD Anti-tumor-initiator activity: NOR 1 Akihisa et al. (2003)
EXD Anti-allergic activity: lgE-mediated mast cell activation (b-
hexosaninidase, LTC4, TNF-a, FceRI b-chain PLCc1, p38
MAPK, IjB-a)
Kishiro et al. (2008)
AP First isolation from the part Luo et al. (2012)
ST Anti-diabetic activity: PTP1B Li et al. (2015)
Selidinin (84) EXD Anti-inflammatory activity (details in the patent) Akihisa et al. (2007)
O-Isobutyroyllomatin (85) ST Anti-diabetic activity: PTP1B Li et al. (2015)
Khellactone (86) AP First isolation from the part Luo et al. (2012)
ST Anti-diabetic activity: PTP1B Li et al. (2015)
30-Senecioyl khellactone (87) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2003)
Anti-tumor-initiator activity: NOR 1
AP Anti-diabetic activity: a-glucosidase Luo et al. (2012)
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Compound class/name Parta Biological activity Reference(s)
Peguangxienin (88) EXD Anti-inflammatory activity: TPA-induced mouse ear edema Akihisa et al. (2007)
(30R,40R)-30-Angeloyl khellactone (89)
(miswritten as isolaserpitin)
RT First isolation from the part Baba et al. (1990b)
FR First isolation from the part Baba et al. (1990a)
EXD Anti-tumor-promoter activity: EBV-EA by TPA
Anti-tumor-initiator activity: NOR 1
Akihisa et al. (2003)
EXD Anti-inflammatory activity (details in the patent) Akihisa et al. (2007)
40-Senecioyl khellactone (90) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2003)
Anti-tumor-initiator activity: NOR 1
Isolemanidin (91) (miswritten as laserpitin) RT First isolation from the part Baba et al. (1990b)
FR First isolation from the part Baba et al. (1990a)
EXD Anti-tumor-promoter activity: EBV-EA by TPA
Anti-tumor-initiator activity: NOR 1
Akihisa et al. (2003)
ST Anti-hyperlipidemic activity: serum HDL:, hepatic TG;
(hepatic TG lipase, differentiation factor 1)
Ogawa et al. (2005b)
EXD Anti-inflammatory activity: TPA-induced mouse ear edema Akihisa et al. (2007)
Pteryxin (92) EXD Anti-tumor-promoter activity: EBV-EA by TPA
Anti-tumor-initiator activity: NOR 1
Akihisa et al. (2003)
EXD Anti-inflammatory activity (details in the patent) Akihisa et al. (2007)
(?)-Cis-(30R,40R)-methylkhellactone (93) AP First isolation from the part Kil et al. (2016)
(-)-Trans-(30R,40S)-methylkhellactone (94), AP First isolation from the part Kil et al. (2016)
Dihydrocoumarin
3,4-Dihydroxanthotoxin (95) AP First isolation from the part Kil et al. (2016)
Phenolics
5-n-Pentadecylresorcinol (96) EXD First isolation from the part Akihisa et al. (2003)
(Z)-p-Coumaryl alcohol (97) AP First isolation from the part Kil et al. (2016)
Acetylenes
Falcarindiol (98) EXD First isolation from the part Akihisa et al. (2003)
AP Anti-diabetic activity: a-glucosidase Luo et al. (2012)
ST Anti-diabetic activity: PTP1B Li et al. (2015)
Acetylenes
(11S,16R,Z)-11,16-Dihydroxyoctadeca-9,17-
dien-12,14-diynyl acetate (99)
EXD First isolation from the part Akihisa et al. (2006)
(10S,15R,Z)-10,15-Dihydroxyheptadeca-8,16-
dien-11,13-diynyl acetate (100)
AP Anti-diabetic activity: a-glucosidase Luo et al. (2012)
(11S,16R,Z)-Octadeca-9,17-dien-12,14-diyne-
1,11,16-triol (101)
AP First isolation from the part Luo et al. (2012)
Angelicol B (102) AP First isolation from the part Luo et al. (2012)
Sesquiterpene
Ashitabaol A (103) SD Anti-oxidative: free radical scavenging Aoki and Ohta
(2010)
Diterpene
Steviol-13-O-b-D-glucopyranoside 19-b-D-
glucopyranosyl ester (104)
LF First isolation from the part Zhou et al. (2012)
Triterpenes
Daucosterol (105) LF First isolation from the part Zhou et al. (2012)
Stigmasterol (106) LF First isolation from the part Zhou et al. (2012)
Triterpenes
Pregnenolone (107) AP Anti-oxidative activity: DPPH radical scavenging Luo et al. (2012)
Nucleoside
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and 4-nitroquinoline-1-oxide in a salmonella assay system
(Park et al. 1997a).
Anti-diabetic activity
The ethanol extract exhibited insulin-like activities through
a pathway independent of peroxisome proliferator-acti-
vated receptor-c (PPAR-c) activation (Enoki et al. 2007).
Long-term ingestion of a powder of A. keiskei improved
blood glucose control and moderately and safely reduced
blood glucose (Ohnogi et al. 2007). A patent is filed on the
beneficial effects of A. keiskei on diabetes (Lee et al. 2013).
Anti-bacterial activity
An exudate of A. keiskei showed anti-bacterial activity
against Helicobacter pylori, suggesting A. keiskei as a
preventive agent for gastritis (Fukuo et al. 2005). A patent
on this exudate is filed for controlling mouth odor by an
anti-bacterial activity against Fusobacterium nucleatum
(Saeki et al. 2013).
Hepato-protective activity
A clinical trial for habitual alcohol drinkers with abnormal
liver function tests also showed that intake of the extracts
significantly reduced c-glutamyl transferase (GGT) levels
(Noh et al. 2015). A patent is filed on the beneficial activity
of an ethanol extract of the roots to improve liver functions
and relieve fatigue (Kim et al. 2006).
Other biological activities
In addition to these activities, an ethanol extract also
showed an anti-hypertensive activity by inhibiting angio-
tensin 1-converting enzyme (ACE) in spontaneously
hypertensive rats, similar to nicotianamine (Shimizu et al.
1999). Green juice of A. keiskei was proven to protect
lymphocytic DNA damage of smokers, which was reported
to potentially reduce the risk of lung cancer in a clinical
trial (Kang et al. 2004). In another clinical study, con-
suming a drink powder of the leaves three times a day for
2 weeks alleviated mild constipation and improved defe-
cation (Kusaba et al. 2008). Deficit of learning and memory
caused by Alzheimer’s disease and aging may be alleviated
by A. keiskei since it has been shown that the plant is
capable of restoring scopolamine-reduced phosphorylation
of cyclic adenosine monophosphate (cAMP) response
element-binding protein (CREB) and expression of brain-
derived neurotrophic factor (BDNF) in the mouse hip-
pocampus (Oh et al. 2013). Topical uses of the extracts
were shown to whiten skin with tyrosinase inhibitory effect
(Higa 1985; Lee et al. 2012b) and promote hair growth
(Sakaguchi et al. 1996) in patent applications.
Biological activities of isolates from A. keiskei
Isolates from A. keiskei have showed diverse biological
activities. Especially two major chalcones, xanthoangelol
(1) and 4-hydroxyderricin (3), have been extensively
Table 3 continued
Compound class/name Parta Biological activity Reference(s)
Adenosine (108) AP First isolation from the part Park et al. (1996)
Saccharide
Sucrose (109) AP First isolation from the part Park et al. (1996)
AP Anti-mutagenic activity (AFB1) Park et al. (1997a)
Acids
Angelic acid (110) RT First isolation from the part Hata and Kozawa
(1961)
Behenic acid (111) RT First isolation from the part Hata and Kozawa
(1961)
Others
1-Cerotol (112) LF First isolation from the part Zhou et al. (2012)
(E)-2,6-Dimethylocta-5,7-diene-2,3-diol
(113)
AP First isolation from the part Luo et al. (2012)
Angelicol A (114) AP Anti-oxidative activity: DPPH radical scavenging Luo et al. (2012)
a Plant part code: WP whole plant, RT root, AP aerial part (including stem and leaf), ST stem, LF leaf, EXD exudate, FR fruit, SD seed; other
source code: Syn synthetic, Com commercial
Angelica keiskei, an emerging medicinal herb with various bioactive constituents… 665
123
Fig. 1 Chemical structures of compounds isolated from A. keiskei
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studied and reported to have anti-tumor, anti-inflammatory,
anti-depressant, anti-obesity, anti-thrombotic, anti-diabetic,
anti-hyperlipidemic, anti-hypertensive, and anti-ulcer
effects. The various effects of isolates will be discussed in
the subsequent sections and summarized in Tables 1, 2 and
3. In our recent research, several compounds from A.
keiskei were evaluated for their effects on heat shock
protein (HSP) expression. HSPs are known to have
Fig. 1 continued
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protective effects on damaged cells, and HSP-inducible
agents may act as prospective agents to protect normal cells
from chemotherapy induced adverse effects. (±)-4,20,40-
Trihydroxy-30-[(6E)-2-hydroxy-7-methyl-3-methylene-6-
octenyl] chalcone (27) of 2 lM increased expressions of
HSF1 (4.3-fold), HSP70 (1.5-fold), and HSP27 (4.6-fold)
proteins at 6 h of treatment and mRNA levels of HSP70
(5.0-fold) and HSP27 (1.5-fold) at 3 h with lower cytotox-
icity than celastrol, a positive control (Kil et al. 2015a).
Anti-ulcer activity
Xanthoangelol (1) and 4-hydroxyderricin (3) inhibited H?,
K?-ATPase of gastric microsomal vesicles which were
prepared from pig fundic mucosa. Additionally, they
downregulated K?-stimulated p-nitrophenyl phosphatase.
Xanthoangelol (1) reduced the formation of stress-induced
gastric lesion as well as acid secretion in rats (Murakami
et al. 1990). Xanthoangelol E (10) was also found to have
the anti-ulcer activity as patented by Murakami et al.
(Murakami et al. 1992).
Anti-bacterial activity
Xanthoangelol (1) and 4-hydroxyderricin (3) showed
antibacterial activities against gram-positive bacteria,
Bacillus subtilis PCI-219, B. subtilis ATCC-6633, B. cer-
eus FDA-5, Staphylococcus aureus 209-P, S. aureus IFO-
3060, S. aureus IFO-3762, and Micrococcus luteus IFO-
12708, but not gram-negative bacteria. Although the anti-
bacterial activities were lower than gentamicin for the
aforementioned bacteria, the anti-bacterial activity of
xanthoangelol (1) against M. luteus IFO-12708 was as
strong as that of gentamicin (MIC 0.76 lg/mL) (Inamori
et al. 1991). Mechanism of anti-bacterial activity of 4-hy-
droxyderricin (3) against S. aureus was elucidated by uti-
lizing a chemical cleavable linker due to its heat sensitivity,
reporting that the isolate inhibits amino acylation of tRNAs
catalyzed by S. aureus seryl-tRNA synthetase which is an
essential enzymatic pathway for bacterial viability (Bat-
tenberg et al. 2013). The two chalcones exhibited anti-
bacterial activities against plant-pathogenic bacteria,
Agrobacteriu tumefaciens IFO-3058, Pseudomonas syr-
ingae pv. phaseolicola IFO-12656, P. syringae pv. tabaci
IFO-3508, and P. stutzeri IFO-12510 (Inamori et al. 1991).
Sumanoto et al. reported anti-bacterial activities of xan-
thoangelol (1), xanthoangelol F (2), 4-hydroxyderricin (3),
and isobavachalcone (4), against gram-positive bacteria,
Escherichia coli NBRC 3301, P. mirabilis NBRC 13300,
P. fluorescens NBRC 3757, B. subtilis NBRC 3757, S.
epidermidis NBRC 12993, and M. luteus NBRC 3333
(Sugamoto et al. 2011).
Chemopreventive activity
Bioactive compounds with anti-tumor-promoter, anti-tu-
mor-initiator, and anti-mutagenic activities may be con-
sidered as chemopreventive therapeutic agents.
Two angular furanocoumarin, (8S,9R)-8-angeloxy-8,9-
dihydrooroseol (79, (30R)-hydroxycolumbianadin) and
archangelicin (81), and three chalcones, xanthoangelol (1),
4-hydroxyderricin (3), and ashitaba-chalcone (11) inhibited
12-O-tetradecanoylphorbol-13-acetate (TPA)-stimulated
32Pi-incorporation of phospholipids of cultured cells.
Xanthoangelol (1) and 4-hydroxyderricin (3) showed anti-
tumor-promoting activities in mouse skin carcinogenesis
induced by 7,12-dimethylbenz[a]anthracene (DMBA) plus
TPA via the modulation of Ca?-calmodulin system
(Okuyama et al. 1991). Isobavachalcone (4) exhibited
inhibitory effects on skin tumor promotion in in vivo two-
stage mouse skin carcinogenesis test (Akihisa et al. 2006).
Inhibitory effects on the induction of Epstein-Barr virus
early antigen (EBV-EA) by TPA in Raji cells were found
for xanthoangelol (1), xanthoangelol F (2), 4-hydroxy-
derricin (3), isobavachalcone (4), xanthoangelol H (12),
xanthoangelol I (14), xanthoangelol J (16), munduleafla-
vanone A (51), munduleaflavanone B (52), isobavachin
(53), prostratol F (54), 8-geranylnaringenin (55, 8-geran-
ulnaringenin), 40-O-geranylnaringenin (56), osthenol (60),
(30R)-hydroxycolumbianidin (79, (8S,9R)-8-angeloxy-8,9-
dihydrooroseol), 30-senecioyl khellactone (87), (30R,40R)-
30-angeloyl khellactone (89, miswritten as ‘‘isolaserapitin’’
in the article), 40-senecioyl khellactone (90), isolemanidin
(91, miswritten as ‘‘laserapitin’’ in the article), and pteryxin
(92) (Akihisa et al. 2003, 2006). Xanthoangelol F (2),
isobavachalcone (4), xanthoangelol I (14), xanthoangelol J
(16), munduleaflavanone B (52), 8-geranylnaringenin (55,
sophoraflavanone A), osthenol (60), selinidin (83), 30-
senecioyl khellactone (87), (30R,40R)-30-angeloyl khellac-
tone (89, miswritten as ‘‘isolaserapitin’’ in the article), 40-
senecioyl khellactone (90), isolemanidin (91, miswritten as
‘‘laserapitin’’ in the article), and pteryxin (92) inhibited
activation of (±)-(E)-methyl-2-[(E)-hydroxy-imino]-5-ni-
tro-6-methoxy-3-hexemide (NOR 1), a NO donor (Akihisa
et al. 2003, 2006). Cynaroside (43, luteolin-7-O-b-D-glu-
copyranoside), luteolin-7-O-b-D-rutinoside (44), hyper-
oside (48, quercetin-3-O-b-D-galactopyranoside), and
sucrose (109) showed anti-mutagenic activities against
aflatoxin B1 (AFB1) (Park et al. 1997a).
Anti-tumor activity
In a previous study, xanthoangelol (1) and 4-hydroxy-
derricin (3) were identified as active compounds to inhibit
tumor growth in Lewis lung carcinoma (LLC)-bearing
mice and to prolong survival time and to suppress
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metastasis to the lung after surgical removal of primary
tumors from an active ethyl acetate fraction of a 50%
ethanol extract (Kimura and Baba 2003; Kimura et al.
2004). The anti-tumor activities of xanthoangelol (1) might
be derived from its inhibitory effects on DNA synthesis in
LLC cells and on tumor-induced neovascularization by
reducing formation of capillary-like tubes by vascular
endothelial cells and adhesion of vascular endothelial
growth factor (VEGF) to human umbilical vein endothelial
cells (HUVECs) (Kimura and Baba 2003). 4-Hydroxy-
derricin (3) also inhibited the DNA synthesis in LLC cells
and the formation of capillary-like tubes, but did not reduce
adhesion of vascular endothelial growth factor (VEGF) to
HUVECs. Instead, it suppressed reduction of lymphocytes,
CD4?, CD8?, and natural killer (NK)-T cells in spleen of
tumor-removed mice (Kimura et al. 2004). Xanthoangelol
(1) induced apoptotic cell death by activation of caspase-3
in neuroblastoma (IMR-32) and leukemia (Jurkat) cells
through a mechanism, independent of Bax/Bcl-2 signal
transduction (Tabata et al. 2005). Their ongoing study
revealed details of the mechanism of action of xanthoan-
gelol (1) inducing apoptosis by triggering oxidative stress
through generating reactive oxygen species and downreg-
ulating antioxidant DJ-1 protein in IMR-32 cells (Motani
et al. 2008). Xanthoangelol (1) showed cytotoxic effects on
several neuroblastoma cell lines including drug-resistant
LA–N-1 and NB-39 cells as well as drug-sensitive IMR-32
and SK-N-SH cells (Nishimura et al. 2007; Motani et al.
2008). Xanthoangelol F (2), 4-hydroxyderricin (3),
isobavachalcone (4), xanthoangelol H (12), and xanthoan-
gelol I (14) were cytotoxic to the NB-39 and IMR-32 cells.
Isobavachalcone (4) was found to induce apoptotic cell
death in the neuroblastoma cells via the mitochondrial
pathway including reduction of procaspase-3 and procas-
pase-9 and induction of Bax level with no cytotoxicity
against normal cells (Nishimura et al. 2007). Xanthoan-
gelol (1) and 4-hydroxyderricin (3) inhibited growth of
human stomach cancer (KATO III) cells through induction
of apoptosis by fragmenting DNA (Takaoka et al. 2008).
4-Hydroxyderricin (3) exhibited cytotoxic activities in
human leukemia (HL60), melanoma (CRL1579), lung
cancer (A549), and stomach cancer (AZ521) cells. The
cytotoxicity to HL60 cells was caused by induction of
apoptosis through inhibiting DNA topoisomerase and
reducing procasparases-3, -8, and -9 (Akihisa et al. 2011).
Anti-diabetic activity
In a genetically diabetic KK-Ay mouse model, xanthoan-
gelol (1) and 4-hydroxyderricin (3) showed insulin-like
activities to enhance glucose uptake and induce pre-
adipocyte differentiation into adipocytes without activating
PPAR-c. 4-Hydroxyderricin (3) also prevented the
progression of diabetes in these mice (Enoki et al. 2007).
On the basis of the preventive effect, a clinical trial was
performed with A. keiskei powder containing 4-hydroxy-
derricin (3), resulting in reduction of blood glucose and
improvement of blood glucose control through increasing
adiponectin in subjects with borderline or mild hyper-
glycemia after 12 weeks of consumption of A. keiskei
(Ohnogi et al. 2007). Xanthoangelol (1), 4-hydroxyderricin
(3), isobavachalcone (4), munduleaflavanone A (51),
demethylsuberosin (59), 30-senecioyl khellactone (87),
falcarindiol (98), and (10S,15R,Z)-10,15-dihydroxyhep-
tadeca-8,16-dien-11,13-diynyl acetate (100) appeared to
inhibit a-glucosidase, which involved in glucose metabo-
lism (Luo et al. 2012). Xanthoangelol (1) and 4-hydroxy-
derricin (3) stimulated skeletal muscle-associated glucose
uptake by inducing glucose transporter 4 (GLUT-4)
translocation, resulting in normal blood glucose level
(Kawabata et al. 2011). Recently, protein tyrosine phos-
phatase 1B (PTP1B) has been suggested as a therapeutic
target for treatment of type 2 diabetes based on its down-
regulating effect on insulin signaling. Li et al. evaluated
isolates from the stems of A. keiskei for their PTP1B
inhibitory effects using oleanolic acid as a positive control.
Xanthoangelol (1), xanthoangelol F (2), 4-hydroxyderricin
(3), xanthoangelol D (9), xanthoangelol E (10), xanthoan-
gelol K (17), xanthoangelol M (20) and bergapten (63,
5-methoxypsoralen; miswritten as ‘‘methoxsalen’’ in the
article) showed strong PTP1B inhibitory effect (IC50
0.82–4.42 lg/mL), together with moderately active four
compounds (selinidin, 83; O-isobutyroyllomatin, 85;
khellactone, 86; falcarindiol, 98, IC50 4.42–11.55 lg/mL)
and a weakly active one (cynaroside, 43, IC50 17.49 lg/
mL). Furthermore, in a kinetic study, xanthoangelol (1)
with IC50 values of 0.82 lg/mL exhibited typical charac-
teristics of the competitive PTP1B inhibitor and in
molecular docking simulations, it was suggested that the
ring B of the chalcone skeleton may anchor in a pocket of
PTP1B (Li et al. 2015).
Nerve cell protective activity
Onogi et al. filed a patent application presenting
angelichalcone (31) with its nerve cell protective effect
(Onogi et al. 2004). In addition, 7-O-b-D-glucopyranosy-
loxy-8-prenyl coumarin (61) was reported for its enhancing
effect on nerve growth factor (NGF) production in mouse
fibroblast L-M cells in a patent (Ohnogi et al. 2002).
Anti-hyperlipidemic activity
Cynaroside (43, luteolin-7-O-b-D-glucopyranoside)
showed hypolipidemic activity when administrated by
intraperitoneal injection in rats (Park et al. 1995).
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Cynaroside (43) and hyperoside (48, quercetin-3-O-b-D-
galactopyranoside) exhibited anti-cholesterogenic activity
by inhibiting HMG-CoA reductase (Park et al. 1997b).
When SHRSP was fed diets containing 4-hydroxyderricin
for 7 weeks, serum very low-density lipoprotein (VLDL)
and hepatic triglycerides (TG) levels were significantly
reduced, without any effect on serum HDL levels. It was
considered that microsomal TG transfer-protein may be
responsible for the decrease in serum VLDL levels and
differentiation factor 1 and fatty acid synthase may induce
the decrease in hepatic TG content (Ogawa et al. 2005b). In
case of isolemanidin (91, miswritten as ‘‘laserapitin’’ in the
article), the serum HDL levels, especially apoE-HDL,
increased and the hepatic TG content decreased, which
might be relevant with a decrease in hepatic TG lipase and
differentiation factor 1, respectively (Ogawa et al. 2005a).
Preventive effects against metabolic syndrome
Ohnogi et al. isolated six new chalcones, 4,20-dihydroxy-30-
[(2E)-6-hydroperoxy-3-methyl-7-methylene-2-octenyl]-40-
methoxychalcone (7), 200-hydroxyxanthoangelol I (15),
4-hydroxy-20,30-(2,3-dihydro-2-hydroxyisopropylfurano)-
40-methoxychalcone (21), 4,2040-trihydroxy-30-[(2E)-6,7-
dihydroxy-3,7-dimethyl-2-octenyl]chalcone (29), 4,20-di-
hydroxy-30,40-{2,3-dihydro-2-[(4E)-1-hydroxy-1,5-dime-
thyl-4-hexenyl]furano}chalcone (30), and angelichalcone
(31) together with xanthoangelol (1) and 4-hydroxy-
derricin (3), and evaluated their effects on adiponectin
mRNA and protein levels. As a result, all isolates, except for
angelichalcone (31), increased expression of adiponectin
mRNA and production of adiponectin in 3T3-L1 adipocytes.
The effects on adiponectin could be expected to prevent
metabolic syndrome through improving insulin resistance
and dyslipidemia (Ohnogi et al. 2012b). Xanthoangelol (1)
and 4-hydroxyderricin (3) suppressed adipocytes differenti-
ation via AMPK and mitogen-activated protein kinase
(MAPK) pathways, which resulted in downregulating
expression of adipocyte-specific transcription factors,
CCAAT/enhancer-binding protein-b (C/EBP-b), C/EBP-a,
and PPAR-c. Inhibitory effects on adipocytes differentiation
could provide preventive effects against obesity and obesity-
related disorders (Zhang et al. 2013).
Anti-hypertensive activity
Xanthoangelol (1), xanthoangelol F (2), 4-hydroxyderricin
(3), xanthoangelol B (5), and xanthoangelol E (10) inhib-
ited phenylephrine-induced vasoconstriction. Among them,
xanthoangelol (1), xanthoangelol F (2), 4-hydroxyderricin
(3), and xanthoangelol E (10) showed the inhibitory effects
through endothelium-dependent production of endothe-
lium-derived relaxing factor (EDRF)/NO. On the other
hand, xanthoangelol B (5) directly inhibited smooth muscle
functions through reducing intracellular free calcium
[Ca2
?]i elevation induced by phenylephrine without
affecting EDRF/NO production. 4-Hydroxyderricin (3)
also suppressed elevation of [Ca2
?]i induced by phenyle-
phrine (Matsuura et al. 2001). Dietary 4-hydroxyderricin
(3) reduced elevation of systolic blood pressure in SHRSP,
which also supported its anti-hypertensive activity (Ogawa
et al. 2005b).
Anti-allergic activity
Xanthoangelol B (5), xanthoangelol C (8), and xanthoan-
gelol E (10) inhibited the compound 48/80-induced his-
tamine release from rat peritoneal mast cells, whereas,
xanthoangelol (1) and 4-hydroxyderricin (3) enhanced it.
Compound 48/80 is one of immunological stimulators,
which activates the mast cell to induce allergic responses
by mediates (Nakata and Baba 2001). Selinidin (83) was
found to suppress degranulation, leukotriene C4 (LTC4)
synthesis, and tumor necrosis factor-a (TNF-a) production
without affecting binding of immunoglobulin E (IgE) with
high affinity IgE receptor (FceRI) and expression of cell
surface FceRI in antigen-stimulated primary mouse bone
marrow-derived mast cells (BMMCs). Selinidin (83)
inhibited tyrosine phosphorylation of FceRI b-chain and
phospholipase C c1 (PLCc1) not FceRI c-chain in BMMCs
upon FceRI stimulation, demonstrating its inhibitory
effects on FceRI-dependent signaling pathway. Phospho-
rylation of p38 MAPK and inhibitory jB-a (IjB-a) were
also downregulated by selinidin (83) (Kishiro et al. 2008).
Anti-inflammatory activity
Xanthoangelol D (9) inhibited activation of nuclear factor-
jB (NF-jB), which was involved in attenuation of basal
and TNF-a-induced endothelin-1 (ET-1), a potent vaso-
constrictor peptide. Its inhibitory effect against NF-jB
inflammatory signaling pathway could be useful for treat-
ing vascular and inflammatory diseases because many
vascular diseases are closely related to the inflammatory
processes (Sugii et al. 2005). A patent covers the anti-
inflammatory activities of seven flavonoids, xanthoan-
gelol (1), xanthoangelol F (2), 4-hydroxyderricin (3),
isobavachalcone (4), deoxyxanthoangelol H (13), mund-
uleaflavanone B (52), and sophoraflavanone A (55, 8-ger-
anylnaringenin), and six coumarins, osthenol (60), selidinin
(84), peguangxienin (88), (30R,40R)-30-angeloyl khellactone
(89), isolemandin (91), and pteryxin (92) from exudates of
A. keiskei (Akihisa et al. 2007). Shin et al. reported that
xanthoangelol (1), 4-hydroxyderricin (3), xanthoangelol B
(5), and 4,20,40-trihydroxy-30-[(6E)-2-hydroxy-7-methyl-3-
methylene-6-octenyl]chalcone (27) showed inhibitory
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activities of IL-6 production in TNF-a-stimulated MG-63
osteosarcoma cells and they have C-40 hydroxyl groups in
common (Shin et al. 2011). Toll-like receptors (TLRs) are
essential for induction of innate immune responses against
invading pathogens, however, overexpression of tran-
scription factors and pro-inflammatory genes by activation
of TLR signaling pathway might cause certain inflamma-
tory diseases. Isobavachalcone (4) reduced overexpression
of iNOS induced by TLR agonists (lipopeptide 2-kDa,
polyriboinosinic polyribocytidylic acid, or LPS) in murine
macrophages (Shin et al. 2013). Xanthoangelol (1) and
4-hydroxyderricin (3) reduced production of LPS-induced
NO and TNF-a, expression of iNOS and COX-2 in
RAW264 mouse macrophages. Moreover, both suppressed
DNA binding activities of activator protein-1 (AP-1) and
NF-jB and phosphorylation level of p65 subunit of NF-jB.
However, two chalcones downregulated only AP-1 not NF-
jB (Yasuda et al. 2014). Inhibitory effects on LPS-induced
NO and expression of iNOS and COX-2 genes were also
found for xanthoangelol B (5), xanthoangelol E (10), and
xanthokeismin A (24) as well as 4-hydroxyderricin (3) and
their mechanisms involved inhibition of IjB degradation
and NF-jB nuclear translocation (Chang et al. 2014).
Anti-oxidative activity
Cynaroside (43, luteolin-7-O-b-D-glucopyranoside) inhib-
ited bromobenzene-induced hepatic lipid peroxidation by
restoring epoxide hydrolase activity in liver of rats (Park
et al. 2002). Xanthoangelol B (5), xanthokeismin A (24),
xanthokeismin B (25), and xanthokeismin C (26) showed
strong superoxide-scavenging activities. Xanthoangelol
(1), 4-hydroxyderricin (3), and isobavachalcone (4)
induced reduced nicotinamide adenine dinucleotide
(phosphate) (NAD(P)H):quinone oxidoreductase 1 (NQO1)
which protects against quinone-mediated oxidative dam-
age. In addition, xanthoangelol (1), isobavachalcone (4),
cynaroside (43, luteolin-7-O-b-D-glucopyranoside), lute-
olin-7-O-b-D-rutinoside (44), kaempferol-3-O-a-D-ara-
binopyranoside (46), isoquercitrin (47, quercetin-3-O-b-D-
glucopyranoside), hyperoside (48, quercetin-3-O-b-D-
galactopyranoside), quercetin-3-O-a-D-arabinopyranoside
(50), pregnenolone (107), and angelicol A (114) showed
DPPH radical scavenging activities (Luo et al. 2012; Kim
et al. 2005). Ashitabaol A (103), an isolate from the seeds
of A. keiskei, was found to be more abundant in the seed
coat during germination through HPLC analysis. Ashita-
baol A (103) exhibited 2,20-azino-bis(3-ethylbenzothiazo-
line-6-sulphonic acid) (ABTS) free radical scavenging
activity and was expected to protect the seed against
oxidative damage induced by free radicals during germi-
nation (Aoki and Ohta 2010). Xanthine oxidase (XO) leads
to formation of free radicals, and cause oxidative damage
to living tissues. Xanthoangelol (1), xanthoangelol F (2),
4-hydroxyderricin (3), isobavachalcone (4), and xan-
thoangelol B (5) showed inhibitory effects on XO activity,
which could be relevant with attenuation of inflammation
(Kim et al. 2014).
Anti-thrombotic activity
Xanthoangelol E (10) was evaluated for effects on
arachidonic acid metabolism in gastric antral mucosa and
platelet of rabbit. Xanthoangelol E (10) showed no sig-
nificant effect on production of PGE2, PGF2a, and their
metabolites in gastric antral mucosal slices, whereas, sup-
pressed production of thromboxane B2 (TXB2) and
12-hydroxy-5,8,10-heptadecatrienoic acid (HHT) from
exogenous arachidonic acid in platelets (Fujita et al. 1992).
Ohkura et al. reported that xanthoangelol (1), xanthoan-
gelol B (5), and xanthoangelol D (9) isolated from the
exudates of A. keiskei suppressed production of TNFa-in-
duced PAI-1, an inhibitor of fibrinolysis, in human
umbilical vein endothelial cells (HUVECs) (Ohkura et al.
2011). Regarding to anti-thrombotic activities, xanthoan-
gelol (1) and 4-hydroxyderricin (3) also exhibited inhibi-
tory effects on platelet aggregation induced by collagen,
platelet-activating factor, and phorbol 12-myristate 13-ac-
etate not thrombin (Son et al. 2014).
Anti-depressant activity
Xanthoangelol (1) was compared to iproniazid, an anti-
depressant nonselective MAO inhibitor. Xanthoangelol (1)
inhibited monoamine oxidase (MAO) in a nonselective
manner and suppressed dopamine b-hydroxylase (DBH).
On the other hands, 4-hydroxyderricin selectively inhibited
MAO-B and mildly suppressed DBH, which was higher
than deprenyl, a selective MAO-B inhibitor. Because MAO
inhibitors have been widely applied for treating depression,
xanthoangelol (1) and 4-hydroxyderricin (3) were sug-
gested as candidates for developing combined antidepres-
sant drug. Additionally, cynaroside (43, luteolin-7-O-b-D-
glucopyranoside) showed strong inhibitory effect against
DBH (Kim et al. 2013).
Anti-viral activity
Park et al. reported that xanthoangelol F (2), 4-hydroxy-
derricin (3), xanthoangelol B (5), xanthoangelol G (6),
xanthoangelol D (9), and xanthokeistal A (28) have inhi-
bitory effects against hydrolysis of influenza virus neu-
raminidase (NA) which has been an effective target to
develop drugs treating patients infected with influenza
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virus. All active compounds showed reversible nonselec-
tive characteristics and xanthoangelol D (9) was the most
potent inhibitor. Furthermore, it was suggested that the
influenza virus NA inhibitory activities of the alkylated
chalcones are associated with their alkyl groups (Park et al.
2011). Because enzymatic activities of a chymotrypsin-like
protease (3CLpro) and a papain-like protease (PLpro) are
essential for a viral life cycle of severe acute respiratory
syndrome corovirus (SARS-CoV), the two viral cysteine
proteases are attractive targets for development of anti-
SARS-CoV drugs. Xanthoangelol (1), xanthoangelol F (2),
4-hydroxyderricin (3), isobavachalcone (4), xanthoangelol
B (5), xanthoangelol G (6), xanthoangelol D (9), xan-
thoangelol E (10), and xanthokeistal A (28) showed com-
petitive inhibitory characteristics to 3CLpro and
noncompetitive ones to PLpro, except for mixed inhibition
manner of isobavachalcone (4) against PLpro. Especially,
xanthoangelol E (10) exhibited the most potent inhibitory
activity, and docking simulation of xanthoangelol E (10) to
both protease revealed that its hydroperoxy group plays a
role in enzyme binding by forming hydrogen bonding (Park
et al. 2015).
Osteogenesis promotive activity
Angelichalcone (31) was presented as an osteogenesis
promotive agent in a patent application (Ohnogi et al.
2004).
Whitening activity
Xanthoangelol (1), 4-hydroxyderricin (3), xanthoangelol H
(12), deoxyxanthoangelol H (13), and deoxydihydroxan-
thoangelol H (41) exhibited inhibitory effects against
melanin formation in B16 melanoma cells with low cyto-
toxicity (Arung et al. 2012).
Discussion
As presented in this review, the pharmacological studies on
A. keiskei and its putative active compounds support a
number of biological activities that can potentially impact
human health. In spite of these reported biological activi-
ties and a number of filed patent applications on this plant,
A. keiskei has not been developed as a pharmaceutical
agent and is currently available on the market as health
drinks. This review presented a summary of the studies
published to date on this promising plant. Although the
majority of these studies are mechanistic, but they can be
used as a solid platform to design and conduct clinical
studies.
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